RxDoctor Payments Data

Bijal Patel, DO

Family Medicine · Bradenton, FLNPI 1184986663

Payments from drug & device makers

$4,952in general payments, 2019–2025

Across 265 payments — averaging $18.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$933
  • Pfizer$701
  • AbbVie$634
  • Exact Sciences$387
  • Lilly USA, LLC$364
  • GSK$311
  • plus $2K from 24 others

What the payments were for

  • Food & beverage$4,952100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,952 in reported general payments places this provider in the 85th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$121,600
Medicare patients
333
Services billed
1,707

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide113$130,948
MounjaroTirzepatide42$56,647
EliquisApixaban25$38,617
XareltoRivaroxaban23$27,659
JanuviaSitagliptin Phosphate17$27,333
Breo ElliptaFluticasone/Vilanterol31$26,522
Breztri AerosphereBudesonide/Glycopyr/Formoterol18$20,385
JardianceEmpagliflozin12$19,481
Repatha SureclickEvolocumab21$12,587
Tresiba Flextouch U-200Insulin Degludec11$9,388
SymbicortBudesonide/Formoterol Fumarate15$5,846
SynthroidLevothyroxine Sodium33$4,078
Albuterol Sulfate HfaAlbuterol Sulfate134$3,855
Levothyroxine Sodium473$3,799
Atorvastatin Calcium561$3,767

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$933$130,948113 claims
Lilly USA, LLCMounjaro, Humulin N$364$57,95453 claims
PfizerEliquis$701$38,61725 claims
Johnson & JohnsonXarelto$63$27,65923 claims
MerckJanuvia$55$27,33317 claims
GSKBreo Ellipta$311$26,52231 claims
AstraZenecaBreztri Aerosphere, Symbicort$217$26,23133 claims
AbbVieSynthroid$634$4,07833 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Bradenton

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →